Semiquantitative Analysis Using Thallium-201 SPECT for Differential Diagnosis Between Tumor Recurrence and Radiation Necrosis After Gamma Knife Surgery for Malignant Brain Tumors

2013 ◽  
Vol 85 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Shigeo Matsunaga ◽  
Takashi Shuto ◽  
Hajime Takase ◽  
Makoto Ohtake ◽  
Nagatsuki Tomura ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Brain Tumors ◽  
Gamma Knife ◽  
Tumor Recurrence ◽  
Radiation Necrosis ◽  
Thallium 201 ◽  
Gamma Knife Surgery ◽  
Semiquantitative Analysis ◽  
Malignant Brain Tumors

scholarly journals Comparison of different methods of neuroimaging in differential diagnosis of the recurrence of malignant brain tumors and radiation necrosis

2016 ◽  
Vol 11 (3) ◽  
pp. 56-63
Author(s):  
Tatiana G. Gribanova ◽  
◽  
Vladimir A. Fokin ◽  
Boris V. Martynov ◽  
Gennady E. Trufanov ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Brain Tumors ◽  
Radiation Necrosis ◽  
Malignant Brain Tumors

Tumor recurrence and survival following gamma knife surgery for brain metastases

2005 ◽  
Vol 102 (Special_Supplement) ◽  
pp. 287-288 ◽  
Author(s):  
Thomas Mindermann
Keyword(s):  
Brain Metastasis ◽  
Brain Metastases ◽  
Gamma Knife ◽  
Tumor Recurrence ◽  
Patient Survival ◽  
Gamma Knife Surgery ◽  
Recurrence Rates ◽  
Term Survival ◽  
Content Type ◽  
Fine Print

Object. The authors evaluated prognostic factors for tumor recurrence and patient survival following gamma knife surgery (GKS) for brain metastasis. Methods. A retrospective review of 101 patient charts was undertaken for those patients treated with GKS for brain metastases from 1994 to 2001. Recurrence rates of brain metastasis following GKS depended on the duration of patient survival. Long-term survival was associated with a higher risk of tumor recurrence and shorter-term survival was associated with a lower risk. The duration of survival following GKS for brain metastases seems to be characteristic of the primary disease rather than the cerebral disease. Conclusions. Recurrence rates of brain metastasis following GKS are related to duration of survival, which is in turn mostly dependent on the nature and course of the primary tumor.

Does gamma knife surgery stimulate cellular immune response to metastatic brain tumors? A histopathological and immunohistochemical study

2005 ◽  
Vol 102 (Special_Supplement) ◽  
pp. 180-184 ◽  
Author(s):  
György T. Szeifert ◽  
Isabelle Salmon ◽  
Sandrine Rorive ◽  
Nicolas Massager ◽  
Daniel Devriendt ◽  
...  
Keyword(s):  
Immune Response ◽  
Brain Tumors ◽  
Gamma Knife ◽  
Cellular Immune Response ◽  
Lymphocytic Infiltration ◽  
Gamma Knife Surgery ◽  
Metastatic Brain Tumors ◽  
Content Type ◽  
Cellular Immune ◽  
Fine Print

Object. The aim of this study was to analyze the cellular immune response and histopathological changes in secondary brain tumors after gamma knife surgery (GKS). Methods. Two hundred ten patients with cerebral metastases underwent GKS. Seven patients underwent subsequent craniotomy for tumor removal between 1 and 33 months after GKS. Four of these patients had one tumor, two patients had two tumors, and one patient had three. Histological and immunohistochemical investigations were performed. In addition to routine H & E and Mallory trichrome staining, immunohistochemical reactions were conducted to characterize the phenotypic nature of the cell population contributing to the tissue immune response to neoplastic deposits after radiosurgery. Light microscopy revealed an intensive lymphocytic infiltration in the parenchyma and stroma of tumor samples obtained in patients in whom surgery was performed over 6 months after GKS. Contrary to this, extensive areas of tissue necrosis with either an absent or scanty lymphoid population were observed in the poorly controlled neoplastic specimens obtained in cases in which surgery was undertaken in patients less than 6 months after GKS. Immunohistochemical characterization demonstrated the predominance of CD3-positive T cells in the lymphoid infiltration. Conclusions. Histopathological findings of the present study are consistent with a cellular immune response of natural killer cells against metastatic brain tumors, presumably stimulated by the ionizing energy of focused radiation.

Ensuring the most effective strategy for cancer treatment of patients with brain tumors.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e14000-e14000
Author(s):  
Elena A. Sheiko ◽  
Elena M. Frantsiyants ◽  
Eduard E. Rostorguev ◽  
Irina V. Kaplieva ◽  
Valeria A. Bandovkina ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Brain Tumors ◽  
Blood Plasma ◽  
Histological Analysis ◽  
Malignant Tumors ◽  
Kinetic Method ◽  
Benign Tumors ◽  
Tumor Removal ◽  
Plastic Tube ◽  
Malignant Brain Tumors

e14000 Background: The purpose of the study was to analyze changes in the total activity of trypsin-like proteinases (TLPs) in the blood plasma in patients with brain tumors for the preoperative differential diagnosis of benign, primary and secondary malignant brain tumors. Methods: TLPs were measured in 164 patients with brain tumors. The blood had been collected from the patients in a standard plastic tube with 3.8% sodium citrate (9:1) 3 days prior to the surgery. Citrate blood was centrifuged; citrated plasma was obtained and used to determine the total TLP activity by the unified kinetic method. Results were compared with the data in donors. Results: TLP activity in 37 (22.6%) of 164 patients was within the normal range (258–402 IU/mL, on the average 333.0±27.1 IU/mL). Benign brain tumors (meningioma) were diagnosed in all 37 patients after the tumor removal and histological analysis. In 74 (45.1%) of 164 patients, TLP activity was within 1158–1626 IU/mL (on the average 1331.0±102.4 IU/mL, p < 0.05), i.e. 3.8-5.3 times higher than the norm in donors (malignancy coefficient on average 4.4±0.3 times). Primary malignant brain tumors (glioblastoma) were diagnosed in all 74 patients after the tumor removal and histological analysis. In 53 (32.3%) of 164 patients, TLP activity was within 1794–2868 IU/mL (on the average 2227.0±174.1 IU/mL, p < 0.05), i.e. 5.9-9.4 times higher than the norm in donors (malignancy coefficient on average 7.3±0.5 times). Secondary malignant brain tumors (metastases) were diagnosed in all 53 patients after the tumor removal and histological analysis. Conclusions: The specificity of the proposed method for the differential diagnosis of brain tumors was very high: for benign tumors - 97.2%, for primary malignant tumors - 98.6% and for secondary malignant tumors - 98.1%. So, TLP activity indices in the blood plasma are an informative auxiliary laboratory test that will help in clarifying and/or confirming the differential diagnosis of brain tumors.

The use of 18F-FDG PET ratios in the differential diagnosis of common malignant brain tumors

2015 ◽  
Vol 39 (6) ◽  
pp. 970-974 ◽  
Author(s):  
Kaan Meric ◽  
Ronan P. Killeen ◽  
Alain S. Abi-Ghanem ◽  
Fatima Soliman ◽  
Fuad Novruzov ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Brain Tumors ◽  
Fdg Pet ◽  
Malignant Brain Tumors ◽  
18F Fdg

Local tumor progression treated with Gamma Knife radiosurgery: differences between patients with 2–4 versus 5–10 brain metastases based on an update of a multi-institutional prospective observational study (JLGK0901)

2020 ◽  
Vol 132 (5) ◽  
pp. 1480-1489 ◽  
Author(s):  
Toru Serizawa ◽  
Masaaki Yamamoto ◽  
Yoshinori Higuchi ◽  
Yasunori Sato ◽  
Takashi Shuto ◽  
...  
Keyword(s):  
Tumor Progression ◽  
Gamma Knife ◽  
Tumor Recurrence ◽  
Prospective Observational Study ◽  
Radiation Necrosis ◽  
Gamma Knife Radiosurgery ◽  
Maximum Diameter ◽  
Local Tumor Progression ◽  
Local Tumor ◽  
Data Set

OBJECTIVEThe Japanese Leksell Gamma Knife (JLGK)0901 study proved the efficacy of Gamma Knife radiosurgery (GKRS) in patients with 5–10 brain metastases (BMs) as compared to those with 2–4, showing noninferiority in overall survival and other secondary endpoints. However, the difference in local tumor progression between patients with 2–4 and those with 5–10 BMs has not been sufficiently examined for this data set. Thus, the authors reappraised this issue, employing the updated JLGK0901 data set with detailed observation via enhanced MRI. They applied sophisticated statistical methods to analyze the data.METHODSThis was a prospective observational study of 1194 patients harboring 1–10 BMs treated with GKRS alone. Patients were categorized into groups A (single BM, 455 cases), B (2–4 BMs, 531 cases), and C (5–10 BMs, 208 cases). Local tumor progression was defined as a 20% increase in the maximum diameter of the enhanced lesion as compared to its smallest documented maximum diameter on enhanced MRI. The authors compared cumulative incidence differences determined by competing risk analysis and also conducted propensity score matching.RESULTSLocal tumor progression was observed in 212 patients (17.8% overall, groups A/B/C: 93/89/30 patients). Cumulative incidences of local tumor progression in groups A, B, and C were 15.2%, 10.6%, and 8.7% at 1 year after GKRS; 20.1%, 16.9%, and 13.5% at 3 years; and 21.4%, 17.4%, and not available at 5 years, respectively. There were no significant differences in local tumor progression between groups B and C. Local tumor progression was classified as tumor recurrence in 139 patients (groups A/B/C: 68/53/18 patients), radiation necrosis in 67 (24/31/12), and mixed/undetermined lesions in 6 (1/5/0). There were no significant differences in tumor recurrence or radiation necrosis between groups B and C. Multivariate analysis using the Fine-Gray proportional hazards model revealed age < 65 years, neurological symptoms, tumor volume ≥ 1 cm3, and prescription dose < 22 Gy to be significant poor prognostic factors for local tumor progression. In the subset of 558 case-matched patients (186 in each group), there were no significant differences between groups B and C in local tumor progression, nor in tumor recurrence or radiation necrosis.CONCLUSIONSLocal tumor progression incidences did not differ between groups B and C. This study proved that tumor progression after GKRS without whole-brain radiation therapy for patients with 5–10 BMs was satisfactorily treated with the doses prescribed according to the JLGK0901 study protocol and that results were not inferior to those in patients with a single or 2–4 BMs.Clinical trial registration no.: UMIN000001812 (umin.ac.jp)

Sign in / Sign up

Export Citation Format

Share Document